The firm said the company Forte Pharma - which it announced buying last year - saw steady growth in sales in France. Laboratories Forte Pharma has three lines of finished supplement products - slimming, health, and beauty - which are sold in France, Belgium, Spain and Italy. In the last four years it has multiplied its sales by five. The move to take it over paid off according to Natraceutical, which said the offshoot has seen further growth into the Austrian and Spanish markets. Natraceutical said the strategic plan for the food supplements division will see the firm invest in publicity and marketing for further expansion of Forte Pharma. This division's turnover for Q3 was €49m. EBIDTA was €8m which will be "especially affected during the last quarter of the year by the investments in advertising campaigns," the firm said. Natraceutical's ingredients division saw sales of €74m. A figure which is expected to be boosted following the takeover of the beta-glucan ingredient Viscofiber. Natraceutical expects this ingredient to bolster sales by €15m by 2012. The firm acquired the concentrate from the Canadian company Cevena Bioproducts in a deal worth €2m earlier this year. The group also acquired Cevena's patents, clinical analyses, clients and distribution contracts. The company branded the acquisition as a "further step towards the consolidation of its international business in the functional foods sector."The move would broaden the company's fibre offering and could also be a shot-in the arm for beta-glucan, as Natraceutical has really been pushing the use of fibre over the last few years and is likely to continue so with beta-glucan. Beta-glucan has been gathering a wealth of scientific backing supporting its role in a number of health arenas. Viscofiber is said to be the "only high-viscosity and high-concentration" oat and barley concentrate commercially available. Natraceutical said that the ingredient has 12 times as much soluble fibre than oat bran. A spokesperson said: "The continuous advances in Natraceutical's R&D department allowed the group in 2006 to diversify its business and expands its activity area from the production of functional ingredients and active principles for food, cosmetics and pharma, to the final consumer via the acquisition of Forte Pharma." Further figures were not released by the firm.